Brought to you by 
ArQule generates libraries for Pfizer for up to $117mm
10 Aug 2005
Executive Summary
ArQule could receive up to $117mm from Pfizer under terms of a four-and-a-half year deal in which it will use its parallel synthesis combinatorial chemistry technologies to generate compound libraries for its partner. Pfizer gets worldwide exclusive rights to all compounds developed, and pays (uf)$16mm up front for research and development, about $50.5mm total in annual committed license fees, and another $50.5mm in developmental milestones.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ArQule generates libraries for Pfizer for up to $117mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice